TCT CONNECT-385 Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease: A Secondary Analysis From ORBITA
Christopher Rajkumar(Imperial College Healthcare NHS Trust), Rasha Al‐Lamee(Imperial College Healthcare NHS Trust), Neil Ruparelia(John Radcliffe Hospital), Alexandra N. Nowbar(Barking, Havering And Redbridge University Hospitals NHS Trust), Laura Amarin(Lung Institute), Niall Keenan(West Hertfordshire Hospitals NHS Trust), Matthew Shun‐Shin(Imperial College London), Ricardo Petraco(Imperial College London), Robert Gerber(East Sussex Healthcare NHS Trust), Kare Tang(Essex Cardiothoracic Centre), James F. Howard(University of North Carolina at Chapel Hill), Sukhjinder Nijjer(Imperial College London), John R. Davies(St James's University Hospital), Iqbal Malik(Imperial College Healthcare NHS Trust), Ramzi Khamis(Imperial College London), Thomas Keeble(Essex Cardiothoracic Centre), Gajen Kanaganayagam(St Thomas' Hospital), Peter O’Kane(Royal Bournemouth Hospital), Graham D. Cole(Imperial College Healthcare NHS Trust), Takayuki Warisawa(St. Marianna University School of Medicine), Dárrel P. Francis(Lung Institute), Henry Seligman, Christopher Cook(Imperial College London), Sayan Sen(Imperial College Healthcare NHS Trust), Andrew Sharp(University Hospital of Wales), Ravi Assomull(Imperial College Healthcare NHS Trust), Michael Foley(Imperial College Healthcare NHS Trust), Joban Sehmi(National Health Service), Yousif Ahmad(Imperial College London)
Cited by 1
Related Papers
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
|The Lancet|2017|1k
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
|New England Journal of Medicine|2021|979
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2022|566